While ipilimumab has not independently been associated with SJS/TEN-like reactions, emerging evidence suggests anti-PD-1/PD-L1 therapies are associated more frequently with SJS/TEN-like reactions (Figures 1A–C) than true SJS/TEN (17, 18). This evidence concerns the gene CD274 and toxic epidermal necrolysis.